Market-Moving News for June 13th
$CERO
$LGVN
$TSLA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/24/2024 | $120.00 → $125.00 | Underweight | Wells Fargo | |
| 10/24/2024 | $236.00 → $238.00 | Hold | Truist | |
| 10/24/2024 | $165.00 → $195.00 | Hold | Jefferies | |
| 10/24/2024 | $245.00 → $255.00 | Neutral | Cantor Fitzgerald | |
| 10/24/2024 | $230.00 → $250.00 | Neutral | Goldman | |
| 10/24/2024 | $236.00 → $249.00 | Outperform | RBC Capital Mkts | |
| 10/24/2024 | $254.00 → $278.00 | Buy | Canaccord Genuity | |
| 9/25/2024 | $300.00 → $310.00 | Overweight | Piper Sandler |
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - Tesla, Inc. (0001318605) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
NEW YORK, Nov. 19, 2024 /PRNewswire/ -- SunCar Technology Group Inc. (NASDAQ:SDA), a leading innovator in cloud-based B2B auto services and auto e-insurance in China, is pleased to announce its inclusion in the NASDAQ Golden Dragon China Index, marking an important milestone in the Company's growth journey. The NASDAQ Golden Dragon China Index is a benchmark for tracking Chinese companies listed on U.S. exchanges, offering investors a window into the dynamic growth opportunities within China's economy, particularly in sectors like digital services, technology, new consumer markets, and clean energy. This prestigious index includes leading Chinese companies like Alibaba (NYSE:BABA), JD.com (
SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug Application (IND) for Phase 1 clinical trials of its lead compound, CER-1236, in acute myelogenous leukemia (AML). Interim CEO Chris Ehrlich commented, "Following our productive discussions with FDA, we look forward to initiating our first in-human trial of CER-1236 in
Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C meeting with U.S. FDA confirmed ELPIS II is pivotal and, if positive, acceptable for Biological License Application (BLA) submission for full traditional approvalPositive data from the Phase 2a clinical trial (CLEAR MIND) evaluating Lomecel-B™ in Alzheimer's disease presented in Featured Research Oral Presentation at Alzheimer's Association International Conference® (AAIC)Total Revenue for the first nine months of 2024 increased 177% year-over-year to $1.8 million, primarily due to the successful initiation of contract manufacturing services and increas
SC 13G/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
Wells Fargo reiterated coverage of Tesla with a rating of Underweight and set a new price target of $125.00 from $120.00 previously
Truist reiterated coverage of Tesla with a rating of Hold and set a new price target of $238.00 from $236.00 previously
Jefferies reiterated coverage of Tesla with a rating of Hold and set a new price target of $195.00 from $165.00 previously
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
10-Q - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero
MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. "I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors," said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron. "Her exte
MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Roger Hajjar, MD, Director of the Gene and Cell Therapy Institute at Mass General Brigham, has been elected to the Longeveron Board of Directors. Dr. Hajjar is an internationally recognized scientist whose cardiac gene therapy discoveries have spurred clinical trials for heart failure, whose methodologies for cardiac-directed gene transfer are currently utilized by investigators around the world, and who was appointed as the inaugural director of the
MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call Details: Conference Call Number:1.877.407.0789Conference ID:13749428 Call me™ Feature:Click HereWebcast:Click Here An archived replay of the webcast will be available on the "Events & Presentations" se
In the third quarter, we produced approximately 470,000 vehicles, delivered approximately 463,000 vehicles and deployed 6.9 GWh of energy storage products. Production Deliveries Subject to operating lease accounting Model 3/Y 443,668 439,975 3% Other Models 26,128 22,915 1% Total 469,796 462,890 3% Tesla will post its financial results for the third quarter of 2024 after market close on Wednesday, October 23, 2024. At that time, Tesla will issue a brief advisory containing a link to the Q3 2024 update, which will be available on Tesla's Investor Relations website. Tesla management will hold a live question and answer webcast that day a
Adjusted EBITDA Increased to $6.4 Million for the First Half of 2024 Conference Call and Webcast on September 16th at 8 AM ET NEW YORK, Sept. 16, 2024 /PRNewswire/ -- SunCar Technology Group Inc. (the "Company" or "SunCar") (NASDAQ:SDA), an innovative leader in cloud-based B2B software-focused auto services and auto e-insurance in China, today provided a business update and reported financial results for the first half of fiscal year 2024. First Half 2024 Financial Results Total revenue increased by 27% to $203.1 million for the six months ended June 30, 2024, from $159.4 million for the six months ended June 30, 2023.Auto Services ' revenue increased by 9% to $107.5 million for the six mo
To gain an edge, this is what you need to know today. GDP Brings Buying Please click here for an enlarged chart of Invesco QQQ Trust Series 1 (NASDAQ:QQQ). Note the following: The chart shows a drop in QQQ. The drop in QQQ was triggered by speculative sentiment pulling back. As a reader of The Arora Report, you knew in advance that speculative sentiment could fall as a result of Tesla Inc (NASDAQ:TSLA) earnings. The chart shows that QQQ is approaching the support zone. RSI on the chart shows that QQQ is now oversold. Oversold markets tend to bounce. The chart shows that the volume was low on the selloff. This indicates a lack of conviction in selling. Especially hard hit in
Honda Motor Co. (NYSE:HMC) will reduce its production of gasoline vehicles in China by 19% starting this October, marking a strategic shift toward electric vehicles. The Japanese automaker will cease operations of one production line at its joint venture Dongfeng Honda, which has an annual capacity of 240,000 units, beginning in November. Additionally, in October, GAC Honda, another of its facilities with a capacity of 50,000 units annually, will be completely shut down. These changes are part of Honda's effort to accelerate the “steady shift” to EVs, reported Bloomberg. Honda’s production capacity in China, currently around 1.5 million units, will see a reduction of 19% due to
https://x.com/elonmusk/status/1816478001884004816https://x.com/elonmusk/status/1815907844434112999